Literature DB >> 22559853

Understanding the kidneys' role in blood glucose regulation.

Curtis L Triplitt1.   

Abstract

While not traditionally discussed, the kidneys' contributions to maintaining glucose homeostasis are significant and include such functions as release of glucose into the circulation via gluconeogenesis, uptake of glucose from the circulation to satisfy their energy needs, and reabsorption of glucose at the level of the proximal tubule. Renal release of glucose into the circulation is the result of glycogenolysis and gluconeogenesis, respectively involving the breaking down and formation of glucose-6-phosphate from precursors (eg, lactate, glycerol, amino acids). With regard to renal reabsorption of glucose, the kidneys normally retrieve as much glucose as possible, rendering the urine virtually glucose free. The glomeruli filter from plasma approximately 180 grams of D-glucose per day, all of which is reabsorbed through glucose transporter proteins that are present in cell membranes within the proximal tubules. If the capacity of these transporters is exceeded, glucose appears in the urine. The process of renal glucose reabsorption is mediated by active (sodium-coupled glucose cotransporters) and passive (glucose transporters) transporters. In hyperglycemia, the kidneys may play an exacerbating role by reabsorbing excess glucose, ultimately contributing to chronic hyperglycemia, which in turn contributes to chronic glycemic burden and the risk of microvascular consequences. This article provides an extensive review of the kidneys' role in normal human physiology, the mechanisms by which they contribute to glucose regulation, and the potential impact of glucose imbalance on the kidneys.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22559853

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  21 in total

1.  Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes.

Authors:  Loretta Fala
Journal:  Am Health Drug Benefits       Date:  2015-03

2.  Invokamet (Canagliflozin plus Metformin HCl): First Fixed-Dose Combination with an SGLT2 Inhibitor Approved for the Treatment of Patients with Type 2 Diabetes.

Authors:  Loretta Fala
Journal:  Am Health Drug Benefits       Date:  2015-03

3.  Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma.

Authors:  Edward Sanders; Svenja Diehl
Journal:  Oncoscience       Date:  2015-02-17

4.  Hnf4a deletion in the mouse kidney phenocopies Fanconi renotubular syndrome.

Authors:  Sierra S Marable; Eunah Chung; Mike Adam; S Steven Potter; Joo-Seop Park
Journal:  JCI Insight       Date:  2018-07-26

Review 5.  Metabolic reprogramming in renal cancer: Events of a metabolic disease.

Authors:  Samik Chakraborty; Murugabaskar Balan; Akash Sabarwal; Toni K Choueiri; Soumitro Pal
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2021-05-06       Impact factor: 11.414

Review 6.  Emerging treatments in type 2 diabetes: focus on canagliflozin.

Authors:  Marek Rosiak; Susanna Grzeszczak; Dariusz A Kosior; Marek Postuła
Journal:  Ther Clin Risk Manag       Date:  2014-08-21       Impact factor: 2.423

7.  A soluble activin receptor type IIB does not improve blood glucose in streptozotocin-treated mice.

Authors:  Qian Wang; Tingqing Guo; Jennifer Portas; Alexandra C McPherron
Journal:  Int J Biol Sci       Date:  2015-01-05       Impact factor: 6.580

8.  Renal glucose release during hypoglycemia is partly controlled by sympathetic nerves - a study in pigs with unilateral surgically denervated kidneys.

Authors:  Sabine J Bischoff; Martin Schmidt; Thomas Lehmann; Matthias Schwab; Georg Matziolis; Alexander Saemann; René Schiffner
Journal:  Physiol Rep       Date:  2015-11

Review 9.  Practical combination therapy based on pathophysiology of type 2 diabetes.

Authors:  Philip A Levin
Journal:  Diabetes Metab Syndr Obes       Date:  2016-10-31       Impact factor: 3.168

10.  The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.

Authors:  Sam Tsz Wai Cheng; Lihua Chen; Stephen Yu Ting Li; Eric Mayoux; Po Sing Leung
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.